Research Papers:

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy

Hojjat Ahmadzadehfar _, Stephan Schlolaut, Rolf Fimmers, Anna Yordanova, Stefan Hirzebruch, Carl Schlenkhoff, Florian C. Gaertner, Zool Hilmi Awang, Stefan Hauser and Markus Essler

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:103108-103116. https://doi.org/10.18632/oncotarget.21600

Metrics: PDF 1529 views  |   HTML 3545 views  |   ?  


Hojjat Ahmadzadehfar1,*, Stephan Schlolaut1,*, Rolf Fimmers2, Anna Yordanova1, Stefan Hirzebruch1, Carl Schlenkhoff1, Florian C. Gaertner1, Zool Hilmi Awang1, Stefan Hauser3 and Markus Essler1

1Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

2Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Germany

3Department of Urology, University Hospital Bonn, Bonn, Germany

*These authors contributed equally to this work

Correspondence to:

Hojjat Ahmadzadehfar, email: [email protected]

Keywords: 177Lu, overall survival, PSMA, radioligand therapy, prostate cancer

Received: August 25, 2017     Accepted: October 04, 2017     Published: October 07, 2017


Prostate-specific membrane antigen (PSMA) is a promising target for the diagnosis of and therapy for metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to measure overall-survival (OS) in mCRPC patients who received either abiraterone or enzalutamide prior to PSMA therapy. The second aim of this study was to analyse the predictors of OS according to different pre-therapeutic parameters and also the responses to the first cycle of radioligand therapy (RLT) base on PSA level. Patients with mCRPC and a history of therapy with either abiraterone or enzalutamide or both, were included in this study. Different laboratory tests and pre-therapeutic parameters have been included into the analysis. One-hundred patients received a total of 347 cycles of Lu-PSMA (median: three cycles). 69 patients showed a decline in PSA two months after the first cycle, and 38 of those patients showed a PSA decline of = > 50%. The median OS was 60 weeks. In the multivariate analysis, the level of albumin, AST and haemoglobin, existence of liver metastases and a decline of > 14% in PSA level had a significant impact on overall-survival. The median OS is significantly longer in patients without hepatic involvement, with high levels of albumin and Hb and low levels of AST. A decline in PSA levels of more than 14% was the most important response parameter with regard to overall survival.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21600